Genetic Technologies Announces Record Number of BREVAGen(TM) Tests

Genetic Technologies Announces Record Number of BREVAGen(TM) Tests 
June Quarter Delivers Growth of 48.6% 
MELBOURNE, AUSTRALIA -- (Marketwired) -- 07/01/13 --  Genetic
Technologies Limited (ASX: GTG) (NASDAQ: GENE) announces that a
record number of BREVAGen(TM) test samples were received during the
quarter ended June 30, 2013. Total patient samples received during
the quarter was 599, representing growth of more than 48% over the
preceding March quarter, demonstrating a significant increasing trend
in market traction.  
Total BREVAGen(TM) test samples received during the 2013 financial
year was 1,547, representing growth of more than 272% over the
preceding 2012 financial year. 
Encouragingly, the quarter on quarter percentage growth in the number
of BREVAGen(TM) samples received has been progressively increasing in
each of the eight completed quarters since the test was launched in
the U.S. market in July 2011. Further, the samples currently being
received are generated from a broad mix of U.S. geographical sales
territories, demonstrating the growing acceptance of the test across
the wider market. 
About Genetic Technologies Limited
 Genetic Technologies was an early
pioneer in recognizing important new applications for "non-coding"
DNA (Deoxyribonucleic Acid). The Company has since been granted
patents in 24 countries around the world, securing intellectual
property rights for particular uses of non-coding DNA in genetic
analysis and gene mapping across all genes in all species. Its
business strategy is the global commercialization of its patents
through an active out-licensing program and the global expansion of
its oncology and cancer management diagnostics portfolio. Genetic
Technologies is an ASX and NASDAQ listed company with operations in
the USA and Australia. For more information, please visit 
Safe Harbor Statement
 Any statements in this press release that
relate to the Company's expectations are forward-looking statements,
within the meaning of the Private Securities Litigation Reform Act.
The Private Securities Litigation Reform Act of 1995 (PSLRA)
implemented several significant substantive changes affecting certain
cases brought under the federal securities laws, including changes
related to pleading, discovery, liability, class representation and
awards fees. Since this information may involve risks and
uncertainties and are subject to change at any time, the Company's
actual results may differ materially from expected results.
Additional risks associated with Genetic Technologies' business can
be found in its periodic filings with the SEC. 
Ms. Alison J. Mew 
Chief Executive Officer
Genetic Technologies Limited
Phone: +61 3 8412 7000 
Laura Forman (USA)
Blueprint Life Science Group
+1 (415) 375 3340, Ext. 103 
Press spacebar to pause and continue. Press esc to stop.